EQS-News

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome - Seite 3

Clinical development of IV RLF-100 in non-COVID-19-induced ARDS is also under consideration.

Inhaled formulation: Relief will decide on additional clinical development pathways for inhaled RLF-100 in patients with moderate to severe COVID-19-induced lung injury, leveraging the learnings from the study by Prof. Leuppi.

Relief also plans to initiate a phase 2 dose-finding study with inhaled RLF-100 in pulmonary sarcoidosis in Europe in the second half of 2021.

Additional indications such as Beryllium Disease and checkpoint inhibitor-induced Pneumonitis are under consideration.

###

ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100^TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. In January 2021, AdVita and Relief announced the signing of a binding term sheet for Relief to acquire all shares of AdVita to expand the scope of development of inhaled aviptadil. The transaction is expected to close in the second quarter of 2021. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

Follow us on LinkedIn.

ABOUT ADVITA LIFESCIENCE GMBH
AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and strategies to improve the therapy and diagnosis of rare lung diseases.

CORPORATE CONTACTS: RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA